While most people have heard of THC and CBD, the cannabis plant contains over 100 different cannabinoids, many of which are only beginning to be studied by scientists. Two of the most intriguing are CBG (cannabigerol) and CBC (cannabichromene). These lesser-known cannabinoids are gaining attention for their potential health benefits, unique roles in the cannabis plant, and promising therapeutic applications.
Understanding CBG and CBC helps reveal just how complex cannabis chemistry is, and why future research may unlock new medical uses for the plant.
What Are Cannabinoids?
Cannabinoids are naturally occurring chemical compounds found in cannabis that interact with the body’s endocannabinoid system (ECS). The ECS is a biological network that helps regulate processes like mood, inflammation, appetite, sleep, and immune responses.
The most famous cannabinoids are:
THC (tetrahydrocannabinol) – the psychoactive compound responsible for the “high”
CBD (cannabidiol) – a non-intoxicating compound widely used for wellness
But cannabinoids like CBG and CBC play important roles as well, both within the plant itself and potentially within the human body. Research suggests that these compounds may contribute to the “entourage effect,” the idea that cannabis compounds work better together than in isolation.
Cannabigerol (CBG): The “Mother Cannabinoid”
CBG is often called the “mother cannabinoid” because it acts as a chemical precursor to several other cannabinoids, including THC, CBD, and CBC.
In the early stages of cannabis plant growth, cannabinoids exist mainly in the form of CBGA (cannabigerolic acid). As the plant matures, enzymes convert CBGA into other cannabinoids such as THC and CBD. Because most CBGA converts into other compounds, very little CBG remains in mature plants, which is why it’s typically found in low concentrations.
Potential Health Benefits of CBG
Although research is still emerging, early studies suggest several potential therapeutic effects.
Inflammation – So far, CBG has shown promise in reducing inflammation. A study investigating inflammatory bowel disease found that CBG reduced inflammation in colitis among mice models.
Neuroprotective potential – CBG may help protect nerve cells. A preclinical study found it improved motor deficits and preserved neurons in a model of Huntington’s disease.
Glaucoma and eye health – CBG may help reduce intraocular pressure, which is relevant for glaucoma treatment.
Because it is non-intoxicating, CBG is gaining popularity in oils, capsules, and wellness products. Unlike THC, CBG does not produce a psychoactive “high,” making it appealing to consumers seeking potential therapeutic benefits without cognitive impairment. CBG may have important implications for reducing inflammation, and helping with other conditions.
Cannabichromene (CBC): The Overlooked Cannabinoid
CBC is another non-psychoactive cannabinoid first discovered in the 1960s. Despite being one of the most abundant cannabinoids in some cannabis strains, it has received far less research attention than THC or CBD.
Like other cannabinoids, CBC interacts with the endocannabinoid system, but it appears to act differently from many of its counterparts. Research suggests CBC may interact strongly with TRPV1 and TRPA1 receptors, which are involved in pain perception and inflammation.
Potential Health Benefits of CBC
Early scientific studies suggest several promising areas of therapeutic potential.
Anti-inflammatory – Preclinical research suggests that CBC may also help reduce inflammation associated with chronic colitis. In a mouse model of inflammatory bowel disease (IBD), CBC significantly reduced markers of intestinal damage, including colon inflammation, intestinal permeability, tissue erosion, and inflammatory enzyme activity.
Mood support – Some research suggests CBC may contribute to mood-enhancing effects when combined with other cannabinoids.
Anticonvulsant Properties – Early research suggests that CBC may have anti-seizure properties similar to CBD. Animal studies have shown that CBC can reduce seizure activity in models of epilepsy, including Dravet syndrome, and in some cases at lower doses than CBD. Researchers believe CBC and other cannabinoids may contribute to the effectiveness of full-spectrum cannabis extracts used for seizure management, though more research is needed to confirm these effects in humans.
Antibacterial – Early research suggests that CBC may have strong antibacterial effects, particularly against Gram-positive bacteria such as Staphylococcus aureus, including antibiotic-resistant strains like MRSA.
Why Lesser-Known Cannabinoids Matter
While THC and CBD dominate the cannabis conversation, researchers increasingly believe that minor cannabinoids like CBG and CBC could hold significant therapeutic potential.
Several factors make them especially interesting:
Different cannabinoids interact with different receptors throughout the body, meaning each compound may produce unique therapeutic effects. In addition, research suggests cannabis compounds may work synergistically through what is known as the entourage effect, where minor cannabinoids like CBG and CBC may enhance or modify the effects of more well-known compounds such as THC and CBD.
As cannabis research expands, compounds like CBG and CBC may lead to new treatments for inflammation, neurological disorders, and chronic pain.
The Future of Cannabinoid Research
Scientific interest in cannabis chemistry is growing rapidly as regulations evolve and research expands. While most studies on CBG and CBC are still preclinical, early findings suggest these cannabinoids may hold meaningful therapeutic potential. As more clinical research emerges, these lesser-known compounds could play an important role in the future of cannabis-based medicine and wellness.
